Indeed, it has consistently been reported that among HER2+ tumors, all intrinsic molecular subtypes by PAM50 analysis can be detected, with non-HER2-enriched BC covering more than a half of all HER2+ tumors [39,40,41]. Here, ERBB2 is linked to breast cancer.